Abstract: The present invention relates to biaryl derivatives of Formula 1, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The biaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in the liver or in muscle due to anti-inflammatory action in macrophages, lipocytes, etc., and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, obesity, non-alcoholic fatty liver, steatohepatitis, osteoporosis or inflammation.

Abstract: A light emitting device includes a first electrode layer, a second conductive semiconductor layer on the first electrode layer, an active layer on the second conductive semiconductor layer, and a first conductive semiconductor layer on the active layer. An AlyGa1-yN layer (where, 0 y?1) is provided over the first conductive semiconductor layer, and an InxGa1-xN pattern (where, 0 x?1) is provided over the AlyGa1-yN layer. A gallium nitride semiconductor layer is provided over the InxGa1-xN pattern; and a pad electrode is provided on the gallium nitride semiconductor layer.

Abstract: Disclosed are a light emitting device, a method of fabricating a light emitting device, a light emitting device package, and a lighting system. The light emitting device includes a first conductive semiconductor layer (112), an InxGa1-xN layer (where, 0<x?1) (151) on the first conductive semiconductor layer (112), a GaN layer (152) on the InxGa1-xN layer (151), a first Aly1Ga1-y1N layer (where, 0<y1?1) (153) on the GaN layer (152), an active layer (114) on the first Aly1Ga1-y1N layer (153), and a second conductive semiconductor layer (116) on the active layer (114).

Abstract: A light emitting device includes a first semiconductor layer having a first conductive dopant, an active layer on the first semiconductor layer, an electron blocking layer on the active layer, a carrier injection layer between the active layer and the electron blocking layer, and a second semiconductor layer having a second conductive dopant on the electron blocking layer. The carrier injection layer includes the first conductive dopant and the second conductive dopant, and the first conductive dopant of the carrier injection layer has a concentration lower than a concentration of the second conductive dopant.

Abstract: The present invention relates to thioaryl derivatives of Formula 1 as defined in the specification, a method for preparing the same, a pharmaceutical composition comprising the same and use thereof. The thioaryl derivatives of Formula 1 according to the present invention promote GLP-1 formation in the gastrointestinal tract and improve insulin resistance in macrophages, pancreas cells, etc. due to anti-inflammatory action, and can accordingly be effectively used for preventing or treating diabetes, complications of diabetes, inflammation, obesity, non-alcoholic fatty liver, steatohepatitis or osteoporosis.

Abstract: A light emitting device includes a first electrode layer (87), a second conductive semiconductor layer (13) on the first electrode layer (87), an active layer (12) on the second conductive semiconductor layer (13), and a first conductive semiconductor layer (11) on the active layer (12). An AlyGa1-yN layer (where, 0<y?1) (16) is provided over the first conductive semiconductor layer (11), and an InxGa1-xN pattern (where, 0<x?1) (15) is provided over the AlyGa1-yN layer (16). A gallium nitride semiconductor layer (14) is provided over the InxGa1-xN pattern (15); and a pad electrode (81) is provided on the gallium nitride semiconductor layer (14).

Abstract: Disclosed are a light emitting device, a method of fabricating a light emitting device, a light emitting device package, and a lighting system. The light emitting device includes a first conductive semiconductor layer (112), an InxGa1-xN layer (where, 0<x?1) (151) on the first conductive semiconductor layer (112), a GaN layer (152) on the InxGa1-xN layer (151), a first Aly1Ga1-y1N layer (where, 0<y1?1) (153) on the GaN layer (152), an active layer (114) on the first Aly1Ga1-y1N layer (153), and a second conductive semiconductor layer (116) on the active layer (114).

Abstract: The present invention relates to novel compounds which are effective as an inhibitor for xanthine oxidase, a process for preparing the same, and a pharmaceutical composition comprising a therapeutically effective amount of the same.

Abstract: A light emitting device includes a first semiconductor layer having a first conductive dopant, an active layer on the first semiconductor layer, an electron blocking layer on the active layer, a carrier injection layer between the active layer and the electron blocking layer, and a second semiconductor layer having a second conductive dopant on the electron blocking layer. The carrier injection layer includes the first conductive dopant and the second conductive dopant, and the first conductive dopant of the carrier injection layer has a concentration lower than a concentration of the second conductive dopant.

Abstract: The present invention relates to novel compounds which are effective as an inhibitor for xanthine oxidase, a process for preparing the same, and a pharmaceutical composition comprising a therapeutically effective amount of the same.